oesophageal cancer
Oncology · 2009–2023
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| nivolumab First-line treatment of advanced or metastatic oesophageal squamous cell carcinoma (OSCC) in patients with tumour cell PD-L1 expression ≥1%, in combination… | Mar 2023 | Recommended | unclear |
| nivolumab Adjuvant treatment of patients with stage II or III oesophageal carcinoma (OC) or gastro-oesophageal junction carcinoma (GOJC) who have received platinum-based… | Jul 2022 | Not recommended | 1 individuals Medical Oncology Group |
| pembrolizumab Locally advanced (Stage III) or metastatic (Stage IV) oesophageal adenocarcinoma (OAC) or oesophageal squamous cell carcinoma (OSCC), or HER2-negative… | May 2022 | Not recommended | input received Pancare Foundation |
| pembrolizumab Locally advanced (Stage III) or metastatic (Stage IV) oesophageal adenocarcinoma, oesophageal squamous cell carcinoma, or HER2-negative adenocarcinoma of the… | Mar 2022 | Not recommended | input received Pancare Foundation |
| nivolumab Adjuvant treatment of stage II or III oesophageal cancer or gastro-oesophageal junction cancer in patients who have received neoadjuvant platinum-based… | Nov 2022 | Recommended with restriction | 1 individuals Medical Oncology Group |
| pembrolizumab Locally advanced (Stage III) or metastatic (Stage IV) oesophageal adenocarcinoma (OAC) or oesophageal squamous cell carcinoma (OSCC), or HER2-negative… | Nov 2021 | Not recommended | input received Pancare Foundation |
| capecitabine Treatment of previously untreated advanced oesophago-gastric cancer in combination with a cisplatin-based regimen in patients with WHO performance status of 2… | Mar 2010 | Recommended with restriction | no section in document |
| capecitabine First-line treatment of previously untreated advanced oesophago-gastric cancer in combination with a platinum-based regimen. | Jul 2009 | Recommended | no section in document |
Who spoke
Pancare Foundation · Medical Oncology Group
What the PBS pays
$826M in government benefit over 2024–25, across 131,848 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| pembrolizumab | $739.6M |
| nivolumab | $85.2M |
| capecitabine | $1M |
Appraised elsewhere
NICE, in England and Wales, has appraised 3 technologies for this condition, recommending 2 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| tislelizumabTislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (terminated appraisal) | TA1068 | terminated | 2025-05 |
| nivolumabNivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer | TA746 | recommended restricted | 2021-11 |
| nivolumabNivolumab for previously treated unresectable advanced or recurrent oesophageal cancer | TA707 | recommended restricted | 2021-06 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 5 of 6 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.